We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-9.52%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$985M
AUM Growth
-$142M
Cap. Flow
+$49.9M
Cap. Flow %
5.07%
Top 10 Hldgs %
58.04%
Holding
76
New
11
Increased
24
Reduced
21
Closed
19

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$54.6M
2
PCVX icon
Vaxcyte
PCVX
+$34.3M
3
GKOS icon
Glaukos
GKOS
+$21.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$21.2M
5
CYH icon
Community Health Systems
CYH
+$17.5M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$38M
2
INSP icon
Inspire Medical Systems
INSP
+$19.5M
3
VTRS icon
Viatris
VTRS
+$15.8M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$14.9M
5
EW icon
Edwards Lifesciences
EW
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 88.54%
2 Miscellaneous 11.4%
3 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KPTI icon
51
Karyopharm Therapeutics
KPTI
$42.4M
$962K 0.1%
257,154
+117,904
+85% +$1.01M
XOMA
52
DELISTED
Xoma
XOMA
$897K 0.09%
45,017
-50,400
-53% -$1.21M
PBYI icon
53
Puma Biotechnology
PBYI
$468M
$816K 0.08%
275,788
-720,314
-72% -$2.25M
ALEC icon
54
Alector
ALEC
$261M
$759K 0.08%
617,418
+417,323
+209% +$679K
EHTH icon
55
eHealth
EHTH
$38.4M
$596K 0.06%
+89,220
New +$811K
AUTL
56
Autolus Therapeutics
AUTL
$623M
$533K 0.05%
343,947
+245,052
+248% +$497K
ACIU icon
57
AC Immune
ACIU
$263M
$188K 0.02%
+100,752
New +$254K
ABSI icon
58
Absci
ABSI
$1.49B
– –
-199,464
Closed -$523K
ARQT icon
59
Arcutis Biotherapeutics
ARQT
$2.99B
– –
-191,158
Closed -$2.66M
AZN icon
60
AstraZeneca
AZN
$252B
– –
-51,331
Closed -$6.73M
DHR icon
61
Danaher
DHR
$152B
– –
-22,209
Closed -$5.1M
DXCM icon
62
DexCom
DXCM
$34.3B
– –
-148,688
Closed -$11.6M
EOLS icon
63
Evolus
EOLS
$587M
– –
-383,045
Closed -$4.23M
EW icon
64
Edwards Lifesciences
EW
$52B
– –
-170,678
Closed -$12.6M
GH icon
65
Guardant Health
GH
$21.7B
– –
-276,036
Closed -$8.43M
HSIC icon
66
Henry Schein
HSIC
$9.98B
– –
-80,303
Closed -$5.56M
MEDP icon
67
Medpace
MEDP
$16.8B
– –
-19,049
Closed -$6.33M
MREO
68
Mereo BioPharma
MREO
$40.3M
– –
-777,890
Closed -$2.72M
SUPN icon
69
Supernus Pharmaceuticals
SUPN
$2.54B
– –
-105,581
Closed -$3.82M
TLT icon
70
PUT
iShares 20+ Year Treasury Bond ETF
TLT
$46.8B
– –
-179,400
Closed -$15.7M
TSVT
71
DELISTED
2seventy bio
TSVT
– –
-1,003,678
Closed -$2.95M
VTRS icon
72
Viatris
VTRS
$18.8B
– –
-1,272,102
Closed -$15.8M
XENE icon
73
Xenon Pharmaceuticals
XENE
$5.81B
– –
-155,540
Closed -$6.1M
XRAY icon
74
Dentsply Sirona
XRAY
$2.22B
– –
-139,656
Closed -$2.65M
ZLAB icon
75
Zai Lab
ZLAB
$2.93B
– –
-102,930
Closed -$2.7M
1 2
3
4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q1 2025 Portfolio in Review

As of Q1 2025, Eversept Partners held 76 positions worth $985M, down 13% from $1.13B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Eversept Partners deployed $49.9M of net new capital in Q1 2025, opening 11 new positions and adding to 24 existing holdings. Its largest new stake was Glaukos: 158,957 shares worth $15.6M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 86% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was GSK, an estimated $38M trimmed.

  • Eversept Partners's largest Q1 2025 buy was Glaukos: 158,957 shares worth $15.6M.
  • Eversept Partners added most to Syndax Pharmaceuticals in Q1 2025, an estimated $54.6M increase.
  • Eversept Partners's biggest Q1 2025 reduction was GSK, cutting an estimated $38M.
  • Eversept Partners fully exited Viatris in Q1 2025, selling an estimated $15.8M.
  • Eversept Partners's ten largest holdings make up 58% of its $985M portfolio in Q1 2025.
  • Eversept Partners opened 11 new positions and closed 19 in Q1 2025.
  • Eversept Partners's portfolio value fell 13% quarter-over-quarter to $985M.

Based on Eversept Partners's 13F filing for Q1 2025, filed 15 May 2025.